Trustmark National Bank Trust Department lessened its holdings in shares of Danaher Co. (NYSE:DHR) by 9.3% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 1,555 shares of the conglomerate’s stock after selling 160 shares during the quarter. Trustmark National Bank Trust Department’s holdings in Danaher were worth $215,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
Other institutional investors have also modified their holdings of the company. Solstein Capital LLC purchased a new position in shares of Danaher during the 4th quarter worth $422,000. Bamco Inc. NY boosted its stake in shares of Danaher by 8.1% during the 4th quarter. Bamco Inc. NY now owns 2,194 shares of the conglomerate’s stock worth $337,000 after acquiring an additional 165 shares during the last quarter. BerganKDV Wealth Management LLC boosted its stake in shares of Danaher by 474.5% during the 4th quarter. BerganKDV Wealth Management LLC now owns 2,752 shares of the conglomerate’s stock worth $422,000 after acquiring an additional 2,273 shares during the last quarter. Rodgers Brothers Inc. purchased a new position in shares of Danaher during the 4th quarter worth $203,000. Finally, BNP PARIBAS ASSET MANAGEMENT Holding S.A. boosted its stake in shares of Danaher by 29.1% during the 4th quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. now owns 176,055 shares of the conglomerate’s stock worth $27,021,000 after acquiring an additional 39,647 shares during the last quarter. Institutional investors and hedge funds own 77.80% of the company’s stock.
In other Danaher news, Chairman Mitchell P. Rales acquired 141,420 shares of the company’s stock in a transaction on Friday, May 29th. The stock was acquired at an average cost of $164.69 per share, with a total value of $23,290,459.80. Following the purchase, the chairman now directly owns 2,298,302 shares of the company’s stock, valued at approximately $378,507,356.38. The purchase was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, CAO Robert S. Lutz sold 33,892 shares of Danaher stock in a transaction on Friday, May 8th. The stock was sold at an average price of $161.68, for a total transaction of $5,479,658.56. Following the completion of the transaction, the chief accounting officer now directly owns 18,950 shares of the company’s stock, valued at $3,063,836. The disclosure for this sale can be found here. Insiders sold a total of 85,318 shares of company stock valued at $13,941,119 over the last three months. Corporate insiders own 11.70% of the company’s stock.
Several brokerages have recently weighed in on DHR. Royal Bank of Canada lifted their price target on shares of Danaher from $159.00 to $173.00 and gave the stock an “outperform” rating in a research note on Monday, May 11th. Robert W. Baird restated a “buy” rating and set a $136.00 price objective on shares of Danaher in a research report on Monday, March 23rd. Needham & Company LLC decreased their price objective on shares of Danaher from $187.00 to $183.00 and set a “buy” rating on the stock in a research report on Friday, May 15th. Zacks Investment Research upgraded shares of Danaher from a “sell” rating to a “hold” rating and set a $160.00 price objective on the stock in a research report on Wednesday, April 15th. Finally, Citigroup raised their price objective on shares of Danaher from $180.00 to $190.00 and gave the company a “buy” rating in a research report on Friday, May 8th. Six equities research analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company. Danaher currently has a consensus rating of “Buy” and a consensus price target of $168.69.
NYSE DHR traded down $7.04 on Thursday, reaching $165.65. The company had a trading volume of 1,552,083 shares, compared to its average volume of 3,452,299. The company has a quick ratio of 1.01, a current ratio of 1.32 and a debt-to-equity ratio of 0.77. The stock has a market capitalization of $118.11 billion, a PE ratio of 37.86, a price-to-earnings-growth ratio of 3.91 and a beta of 0.91. The firm’s 50 day moving average price is $163.30 and its 200 day moving average price is $153.83. Danaher Co. has a 12 month low of $119.60 and a 12 month high of $174.52.
Danaher (NYSE:DHR) last announced its quarterly earnings results on Wednesday, May 6th. The conglomerate reported $1.05 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.00 by $0.05. The company had revenue of $4.34 billion for the quarter, compared to the consensus estimate of $4.32 billion. Danaher had a net margin of 16.85% and a return on equity of 11.52%. Danaher’s revenue for the quarter was up 2.9% compared to the same quarter last year. During the same period in the previous year, the firm posted $1.07 EPS. On average, research analysts expect that Danaher Co. will post 4.88 EPS for the current year.
The firm also recently disclosed a quarterly dividend, which will be paid on Friday, July 31st. Shareholders of record on Friday, June 26th will be paid a $0.18 dividend. The ex-dividend date of this dividend is Thursday, June 25th. This represents a $0.72 dividend on an annualized basis and a dividend yield of 0.43%. Danaher’s payout ratio is currently 16.29%.
Danaher Company Profile
Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The company operates through three segments; Life Sciences, Diagnostics, and Environmental & Applied Solutions. The Life Sciences segment provides mass spectrometers; cellular analysis, lab automation, and centrifugation instruments; microscopes; and genomics consumables.
Featured Article: How Do I Invest in Dividend Stocks
Want to see what other hedge funds are holding DHR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Danaher Co. (NYSE:DHR).
Receive News & Ratings for Danaher Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Danaher and related companies with MarketBeat.com's FREE daily email newsletter.